Read Time:12 Second
MindMed Inc. said Tuesday it’s on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
